["Double-blind" clinical study of a non-steroid anti-inflammatory drug: glucametacine].
A double blind clinical study has been carried out with two non-steroid anti-inflammatory drugs, glucametacine and phenylbutazone in 40 patients suffering from inflammatory and degenerative type arthrorheumopathies, selected and randomised into two groups. Examination of results shows the greater effectiveness of glucametacine (78%)over phenylbutazone (60%). Glucametacine was also statistically (p < 0,05) better from the tolerance point of view.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001847:Bone Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D005944:Glucosamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007213:Indomethacin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D005944:Glucosamine; C010581:glucametacin; D007213:Indomethacin
Studio clinico in "doppio cieco" con un farmaco antiflogistico non steroideo la "glucametacine".